<DOC>
	<DOCNO>NCT01653847</DOCNO>
	<brief_summary>The immune system body 's defense infection disease . After transplantation , body see new organ `` foreign '' try destroy `` reject '' . Immunosuppressive medication help prevent immune system attack transplant organ . The primary purpose study investigate impact two maintenance immunosuppressive regimen . Subjects enroll study randomly select tacrolimus everolimus ( group 1 ) tacrolimus mycophenolate mofetil ( group 2 ) immunosuppression medication . This study enroll adult patient schedule receive kidney transplant . The study design understand mechanism Everolimus regard kidney function transplant recipient . The investigator hypothesis decrease exposure Tacrolimus immune system translate good renal allograft function .</brief_summary>
	<brief_title>Study Recipients Renal Transplant Allograft Evaluate Impact Two Immunosuppressive Regimens</brief_title>
	<detailed_description>Immunosuppressive therapy calcineurin inhibitor ( CNI ) Cyclosporine ( CsA ) Tacrolimus ( Tac ) , radically change field organ transplantation . Ironically , although extensively effectively use kidney transplantation solid organ transplant , CsA Tac cause important adverse renal side effect : acute chronic renal dysfunction , hemolytic-uremic syndrome , hypertension , electrolyte disturbance tubular acidosis . Chronic nephrotoxicity CNI implicate principal cause post-transplant renal dysfunction characterize irreversible progressive tubular atrophy , interstitial fibrosis , focal hyalinosis small renal artery arteriole . Furthermore , class medication associate also , block Interleukin-2 ( IL2 ) production , negative impact regulatory T cell ( T-Regs ) generation ( important subpopulation T helper cell associate positive immunomodulation donor specific hypo responsiveness ) . In renal transplant recipient , complete avoidance calcineurin inhibitor time renal transplant surgery associate increase incidence acute cellular rejection , combination mammalian target rapamycin ( mTOR ) inhibitor full dose CNI show synergistically nephrotoxic associate poor graft outcome . CNI conversion mTOR inhibitor , different time point post-transplant , test promising result , different investigator investigator group . The investigator show Prednisone-free immunosuppression , conversion Tacrolimus mTor inhibitor different time point post transplant safe , associate increase risk acute rejection importantly associate persistent increase regulatory T cell ( Data present American Transplant Congress ( ATC ) 09 2010 ) Recently A2309 study allow Everolimus FDA approve . The A2309 study design combine reduce dose Cyclosporine+Everolimus . Interesting reduce exposure Cyclosporine associate increase rate albumin-creatinine ratio ( ACR ) renal allograft function well maintain compare control group . The A2309 open important question regard mechanism ( ) explain efficacy low dose CNI mTOR inhibitor prevent acute allograft rejection . The present proposal design understand mechanism synergistic effect ( ) low dose CNI mTOR inhibitor ( Everolimus ) control allo-reactive T B cell expand T-Regs . The investigator hypothesis base publish data laboratory ( see preliminary data-Supportive document ) , mTOR inhibitor allow expansion T-Regs low exposure CNI sufficient control allo-reactive T cell . Decrease exposure CNI concomitant increase T-Regs translate well renal allograft function histology .</detailed_description>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Immunosuppressive Agents</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<criteria>1 . Subjects adults 18 70 year age 2 . Subjects either gender ethnic background 3 . Subjects single organ recipient ( kidney ) 4 . Subjects must able understand protocol provide inform consent . 5 . Recipient live donor kidney transplant 6 . Panel reactive antibody ( PRA ) &lt; 20 % 1 . Subjects End Stage Renal Disease ( ESRD ) secondary primary focal segmental glomerulonephritis ( FSGS ) . 2 . Inability fully understand purpose study inability sign inform consent 3 . Subjects significant active infection 4 . Subjects pregnant nursing female 5 . Subjects history severe hyperlipidemia control statin , patient Cholesterol &gt; 400mg/dl 6 . Subjects platelet count &lt; 100,000mm3 , WBC &lt; 2,000mm3 ( clinical practice ) 7 . Subjects , , due existence surgical , medical psychiatric condition , current transplant , opinion investigator , precludes enrollment trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>transplant</keyword>
	<keyword>kidney</keyword>
	<keyword>renal disease</keyword>
</DOC>